financetom
Business
financetom
/
Business
/
ICICI Lombard is the sole insurer to lose premium in September
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ICICI Lombard is the sole insurer to lose premium in September
Oct 15, 2019 12:18 PM

The non-life insurance industry grew at a healthy pace in the month of September. September premium growth for the non-life industry grew by 28.3 percent which compares to an average of 17.2 percent in the first half of FY20. The non-life industry consists of 25 general insurance, 7 specialised health insurance companies.

September business data spells a negative note for ICICI Lombard which has become the sole general insurance company to lose premium in the month of September. The total premium collection for ICICI Lombard in September has fallen by 23 percent which compares to an average fall of 11.8 percent in the first half of FY20. The fall in the premium collection is to be attributed to almost zero contribution coming from the crop insurance segment. Market share for ICICI Lombard has also fallen by 224 basis points in the period between January to September 2019.

As far as other general insurance companies are concerned, the September premium collection for Reliance General grew by 22.5 percent which compares to an average of 24.5 percent in the first half of FY20. September premium for SBI General Insurance also grew by 88 percent which compares to average growth of 50.8 percent in the first half of FY20.

PSU general insurance companies witnessed a strong comeback in the month of September. Premium collection for New India Assurance grew by 15.5 percent on a year on year basis. Market share for the company also saw a jump of 177 basis points in the period between January to September 2019.

September premium collection for National Insurance grew by 181 percent, for United India it grew by 45 percent and for Oriental Insurance it’s grown by 5.5 percent on a year on year basis.

First Published:Oct 15, 2019 9:18 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved